Type of Assessment:
Fibulin-3 in plasma and pleural effusion as a biomarker of mesothelioma
Radiology and Oncology 2025 June 16 [Link] Katja Adamic, Mateja Marc Malovrh, Urska Bidovec Stojkovic, Ales Rozman Abstract Background: Malignant pleural mesothelioma (MPM) is a global health concern linked to asbestos exposure. In Slovenia, regions with high asbestos exposure rates make MPM a significant public health issue. Although thoracoscopic biopsy is the gold standard for…
Read MoreImpact of Multimodal Surgical Resection and Personalized Targeted Therapy on Survival Outcomes in Early-Stage Malignant Pleural Mesothelioma: A Meta-Analysis
Cureus 2025 May 22 [Link] Alexis Quetzalcoatl Vega Morales, Jorge Luis Rivera Gastelum, Alfonso J Massé Ponce, Alexis Agustin A Dunay Silva, Emiliano Banda Dávila, Andrea Virginia Rivera Aguirre, Odalys Brigitte Villares Santillán, Michael David Naranjo Venegas Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited evaluates the efficacy and safety of these…
Read MoreIdentification of a novel prognostic gene signature in pleural mesothelioma: a study based on The Cancer Genome Atlas database and experimental validation
Translational Cancer Research 2025 May 30 [Link] Xinmeng Wang, Yongqin Yang, Wenzhong Yang, Xi Yang, Jinsong Li, Yaru Lin, Zhengliang Li, Jiangyan Li, Wei Xiong Abstract Background: Early detection and prognostic prediction are crucial in improving the survival of patients with pleural mesothelioma (PM). Therefore, this study aimed to develop a gene prognostic risk model…
Read MoreExpression of Heart Development Protein With EGF-Like Domains 1 (HEG1) Decorated With Low-Sulfated Keratan Sulfate in Human Malignant Pleural Mesothelioma
Pathology International 2025 June 17 [Link] Koki Nakashima, Hitomi Hoshino, Zui Zhang, Tomoya O Akama, Nobuyuki Kondo, Seiki Hasegawa, Yoshitaka Sekido, Mana Fukushima, Tamotsu Ishizuka, Motohiro Kobayashi Abstract The glycoform of heart development protein with EGF-like domains 1 (HEG1) recognized by the SKM9-2 monoclonal antibody is a useful diagnostic marker for malignant pleural mesothelioma (MPM).…
Read MoreCharacteristics of Long-Term Survivors With Peritoneal Mesothelioma – Insights From the National Cancer Database
The American Surgeon 2025 June 17 [Link] Himani Bhatt, Deep P Vakil, Luis Quintero, Monique Motta, Maria Vashchenko, Bettsy Rodriguez, Shenae K Samuels, Kumar Jayant, Jonathan Magloire, Christopher J Gannon, Omar H Llaguna Abstract Introduction: Peritoneal mesothelioma (PM) is a rare cancer associated with high mortality. No studies exist using the National Cancer Database (NCDB)…
Read MoreMolecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities
Diagnostics (Basel) 2025 May 24 [Link] Teodora Zahiu, Carmen Mihaela Mihu, Bianca A Bosca, Mariana Mărginean, Lavinia Patricia Mocan, Roxana-Adelina Ștefan, Rada Teodora Suflețel, Carina Mihu, Carmen Stanca Melincovici Abstract Pleural mesothelioma (PM) is a rare disease, which is going to be a global medical concern in the 21st century, because of its aggressiveness, late…
Read MoreVolatile organic compounds in exhaled human breath for the diagnosis of malignant pleural mesothelioma: a meta-analysis
Frontiers in Oncology 2025 May 28 [Link] Tingting Zhao, Xiao Hu , Minghua Peng, Wei Wei, Ninghua Fu, Chen Chen, Zhenguang Chen Abstract Objective: Malignant pleural mesothelioma (MPM) is a relatively rare thoracic tumor with a high mortality rate, making early diagnosis and treatment challenging. The present study evaluated the utility of exhaled volatile organic…
Read MoreExploration of the anticancer properties of Caffeic Acid in malignant mesothelioma cells
Medical Oncology 2025 June 10 [Link] Dayk Muratoglu, Gulseren Turhal, Busra Demirkan, Izel Nermin Baslilar Nimet Sule Yuncu, Asuman Demiroglu-Zergeroglu Abstract Malignant Pleural Mesothelioma (MPM) is the most prevalent type of Mesothelioma and currently has no effective treatment options. This underscores the urgent need to explore new therapeutic agents and innovative strategies. Phenolic acids are…
Read MoreImmune-related gene risk model establishment and role of key gene FUCA1 in malignant pleural mesothelioma
Frontiers in Pharmacology 2025 May 23 [Link] Lin Shi, Dongqi Yuan, Fuyi Zhu, Yuchao He, Ran Zuo, Liwei Chen, Yi Luo, Yu Wang, Dingzhi Huang, Peng Chen, Hua Guo Abstract Background: Malignant pleural mesothelioma (MPM) is a rare type of tumor closely associated with asbestos exposure. Increasing evidence shows that high immuno-heterogeneity reduces the therapeutic…
Read MoreA Case of Duodenal Metastasis From Malignant Pleural Mesothelioma Diagnosed by Gastrointestinal Endoscopy Following Progressive Anemia During Salvage Chemotherapy
Thoracic Cancer 2025 June [Link] Naruhiko Ichiyama, Hiromichi Yamane, Takako Saitou, Masafumi Miura, Ayaka Mimura, Yoko Kosaka, Tatsuyuki Kawahara, Yasunari Nagasaki, Nobuaki Ochi, Hidekazu Nakanishi, Hideyo Fujiwara, Nagio Takigawa Abstract Malignant pleural mesothelioma (MPM) primarily progresses through direct invasion into the lung and pleura and is a refractory tumor in which asbestos exposure is a…
Read More
Skip to content